度普利尤单抗治疗重度慢性手部湿疹的IIb期概念验证研究
这项16周随机双盲安慰剂对照IIb期概念验证试验纳入30例对阿利维A酸应答不足或不耐受的重度慢性手部湿疹患者,按2:1随机接受度普利尤单抗300 mg或安慰剂皮下注射每2周一次。第16周度普利尤单抗组达到HECSI-75的患者比例为95%,安慰剂组为33%;度普利尤单抗耐受性良好,不良事件多为轻度。作者结论为度普利尤单抗有效且耐受良好,但需更大规模、更长疗程的研究提供更多证据。
要点
- 第16周度普利尤单抗组HECSI-75达95%,安慰剂组为33%。
- 度普利尤单抗组瘙痒峰值NRS自基线至第16周最小二乘均值百分比变化为-66.5%,安慰剂组为-25.3%。
- 不良事件两组相似且多为轻度,无严重不良事件,无因不良事件停药。
核心结论
- 度普利尤单抗治疗对阿利维A酸应答不足或不耐受的重度慢性手部湿疹有效且耐受良好。
- 作者指出需更大规模、更长疗程的研究提供更多证据,并可通过更大规模研究比较临床亚型或病因诊断。
研究设计与样本
- 16周随机双盲安慰剂对照概念验证IIb期试验,共随机30例,29例接受研究药物(度普利尤单抗20例,安慰剂9例)。
- 纳入成人重度慢性手部湿疹患者(复发水疱性手部湿疹或慢性裂隙性手部湿疹亚型),对阿利维A酸应答不足或不耐受或医学上不宜使用阿利维A酸。
- 按2:1随机接受度普利尤单抗300 mg或安慰剂皮下注射每2周一次,研究启动时及每4周随访至16周。
- 主要终点为第16周达到手部湿疹严重程度指数评分改善至少75%(HECSI-75)的患者比例。
- 研究注册于ClinicalTrials.gov(标识NCT04512339)。
主要发现
- 第16周度普利尤单抗组95%(95%CI 73.1-99.7)达到HECSI-75,安慰剂组33%(95%CI 9.0-69.1)。
- 瘙痒峰值数值评定量表自基线至第16周最小二乘均值百分比变化:度普利尤单抗组-66.5±10.7(95%CI -88.6至-44.5),安慰剂组-25.3±17.0(95%CI -60.1至9.4)。
- 度普利尤单抗组与安慰剂组不良事件相似,且多为轻度。
- 无严重不良事件,亦无任何不良事件导致研究药物停药。
局限性
- 作者指出需更大规模、更长疗程的研究以提供度普利尤单抗治疗慢性手部湿疹疗效的更多证据。
- 作者指出更大规模研究才可能实现临床亚型或病因诊断之间的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the treatment of hand eczema in other studies. OBJECTIVES: To evaluate the efficacy and safety of dupilumab in adult patients with severe CHE (subtypes recurrent vesicular hand eczema or chronic fissured hand eczema) who have an inadequate response/intolerance to alitretinoin, or when alitretinoin is medically inadvisable. METHODS: In this 16-week, randomized, double-blind, placebo-controlled proof-of-concept phase IIb trial, patients with severe CHE were randomized 2 : 1 to dupilumab 300 mg or placebo subcutaneously every 2 weeks. Patients visited the outpatient clinic at the initiation of the study drug, and every 4 weeks until 16 weeks of treatment. The primary endpoint was the proportion of patients achieving at least a 75% improvement on the Hand Eczema Severity Index score (HECSI-75) at week 16. Adverse events were monitored during each visit. The study was registered on ClinicalTrials.gov (identifier NCT04512339). RESULTS: In total, 30 patients were randomized, and 29 patients received the assigned study drug (dupilumab n = 20, placebo n = 9). At week 16, more patients achieved HECSI-75 in the dupilumab group than in the placebo group {95% [95% confidence interval (CI) 73.1-99.7] vs. 33% [95% CI 9.0-69.1]}. Dupilumab also showed greater least square mean percentage change from baseline to week 16 in peak pruritus Numerical Rating Scale compared with placebo [-66.5 ± 10.7 (95% CI -88.6 to -44.5) vs. -25.3 ± 17.0 (95% CI -60.1-9.4)]. Adverse events were similar for the dupilumab and placebo groups and were mostly mild. There were no serious adverse events, nor did any of the adverse events lead to discontinuation of the study drug. CONCLUSIONS: Dupilumab was efficacious and well tolerated. Larger studies of longer duration are needed to provide more evidence on the -efficacy of dupilumab in CHE. Moreover, larger studies could also enable comparisons between clinical subtypes or aetiological -diagnoses.
引用
- Voorberg AN, Kamphuis E, Christoffers WA, et al. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023. PMID: 37170922. doi:10.1093/bjd/ljad156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。